Immunomedics Reports First Results From Phase Ib Study of 90Y-Clivatuzumab


Ib of 90Y-Clivatuzumab in Patients With Metastatic Pancreatic Cancer After 2 or More Prior Therapies

— Repeated Cycles of 90Y-Clivatuzumab Treatments Extended Survival When
                      Compared to Single Cycle —

      — Low-Dose Gemcitabine in Combination with 90Y-Clivatuzumab
        Significantly Improved Efficacy of Treatment Regimen —

          — Company Planning Phase III Registration Trial —

BARCELONA, Spain, July 3, 2013 (GLOBE NEWSWIRE) — Immunomedics, Inc.
(Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced encouraging results from the Phase Ib study with clivatuzumab labeled with the radioisotope, yttrium-90 (90Y), in patients with metastatic pancreatic cancer who had received at least 2 prior treatments. Results from this trial were reported by Edith Mitchell, MD, from the Kimmel Cancer Center of Thomas Jefferson University in Philadelphia, PA, in an oral presentation at the European Society for Medical Oncology (ESMO) 15th World Congress on Gastrointestinal Cancer.

Clivatuzumab is a humanized antibody developed by the Company for the treatment of pancreatic cancer. It targets a specific tumor marker produced by almost all pancreatic cancers that is not usually present in pancreatitis, normal pancreas or most other normal tissues. The Company has previously reported a median overall survival (OS) of 11.8 months in patients with newly diagnosed, untreated, advanced pancreatic cancer after receiving repeated cycles of the 90Y-labeled antibody in combination with low-dose gemcitabine.1

The current Phase Ib study of clivatuzumab was undertaken in pancreatic cancer patients with two or more prior therapies. For these relapsed patients, there is no agreed standard…Read more

Pharmalive – The Pulse of the Pharmaceutical Industry

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS